STCube Demonstrates Mechanism of Action for Immune Checkpoint Inhibitor 'STT-003' Antibody Combined with Radiation Therapy

[Asia Economy Reporter Hyunseok Yoo] STCube, a bio company developing immuno-oncology drugs, announced on the 14th that it has demonstrated the main mechanism of action of combining the immune checkpoint inhibitor antibody ‘STT-003’ with radiation therapy.

A company official stated, “When radiation is applied alone to kill tumor cells in cancer patients, the expression of immune checkpoint molecules increases and the anti-cancer immune response of immune cells is suppressed, causing various adverse effects. Through animal experiments and various studies, we have proven that combining the innovative drug candidate antibody ‘STT-003’ with radiation therapy allows the anti-cancer immune response to occur normally.”

When radiation therapy is performed alone, intracellular reactive oxygen species (ROS) increase. ROS have a fatal impact on immune cells and normal cells within the tumor microenvironment, suppressing anti-cancer immune function. The company explained that combining the ‘STT-003’ antibody with radiation therapy can inhibit the production of ROS and restore anti-cancer immune function.

Steven H. Lin, MDACC Professor of Radiation Oncology, who will conduct future clinical research, said, “It is highly significant to establish scientific evidence for the clinical application of a treatment method combining the ‘STT-003’ antibody, which can effectively inhibit ROS production in immune cells within the tumor microenvironment, with radiation therapy.” He added, “We plan to apply for a research funding program from the U.S. National Institutes of Health (NIH) to continuously promote joint research with STCube on the radiation combination therapy of the ‘STT-003’ antibody.”

This content was produced with the assistance of AI translation services.